Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

July 31, 2024

Study Completion Date

October 1, 2029

Conditions

Superficial Bladder CancerBladder Cancer

Interventions

DRUG

Metformin

Metformin orally at doses up to 1500 mg twice daily for 3 months.

Trial Locations (3)

NOT_YET_RECRUITING

RadboudUMC, Nijmegen

NOT_YET_RECRUITING

Sint Franciscus Gasthuis, Rotterdam

RECRUITING

Academic Medical Center, Amsterdam

All Listed Sponsors

collaborator

Radboud University Medical Center

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT03379909 - Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer | Biotech Hunter | Biotech Hunter